Executive Vice President, Corporate Affairs, General · RIGEL PHARMACEUTICALS INC (RIGL)

Dolly Vance

A named executive officer of RIGEL PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,194,583

Salary $524,890Stock awards $0

FY2019: $1,181,962

3rd of 5 named executive officers at Rigel Pharmaceuticals by FY2020 total.

5 named officers on file for RIGEL PHARMACEUTICALS, FY2020

Dolly Vance’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • RIGL’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how RIGEL PHARMACEUTICALS’s whole pay program stands against its peers

  • RIGEL PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RIGL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 6, 2021 (DEF 14A).

Free

Get Dolly Vance’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Dolly Vance compensation by year

RIGEL PHARMACEUTICALS Summary Compensation Table · all 5 fiscal years held
In US dollars, as RIGEL PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020
Salary$489,814$489,814$504,508$514,598$524,890
Bonus$0$0$0$0$0
Stock awards$0$0$0$0$0
Option awards$493,380$393,545$863,124$420,682$459,869
Non-equity incentive$159,190$244,907$401,402$239,288$200,770
Pension and deferred compensation$0$0$0$0$0
All other$1,794$1,794$1,794$7,394$9,054
Total$1,144,178$1,130,060$1,770,828$1,181,962$1,194,583

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RIGEL PHARMACEUTICALS INC DEF 14A filed April 6, 2021, accession 0001104659-21-047180, and prior-year filings. Open the filing on EDGAR.

How this page was built: the RIGEL PHARMACEUTICALS INC filed document, accession 0001104659-21-047180. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2021.

$1.1M
$1.1M
$1.8M
$1.2M
$1.2M
FY16
FY17
FY18
FY19
FY20
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option67,253—$2.42
Option37,500—$2.42
Option37,500—$2.42
Option75,000—$2.42
Option45,247—$2.42
Option40,624—$2.00
Option40,626—$2.00
Option15,229—$4.49
Option22,271—$4.49

Per the Outstanding Equity Awards at Fiscal Year-End table in RIGEL PHARMACEUTICALS INC's FY2020 proxy; value at the fiscal year-end close, as the company printed it.

RIGEL PHARMACEUTICALS’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Raul RodriguezPresident and Chief Executive Officer$2,963,884
Dean SchornoExecutive Vice President and Chief Financial Officer$1,202,524
Dolly Vance · this pageExecutive Vice President, Corporate Affairs, General$1,194,583
David SantosExecutive Vice President and Chief Commercial Officer$1,190,602
Wolfgang DummerExecutive Vice President and Chief Medical Officer$730,439

The full RIGEL PHARMACEUTICALS compensation record

free company brief

This page is one person within RIGEL PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the RIGEL PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RIGEL PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Dolly Vance's compensation dossier · One-time report. No refunds.